Denis Drygin's most recent trade in Regulus Therapeutics Inc was a trade of 76,686 Common Stock done at an average price of $0.2 . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Denis Drygin | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.23 per share. | 01 Mar 2022 | 76,686 | 100,000 (0%) | 0% | 0.2 | 17,638 | Common Stock |
| Regulus Therapeutics Inc | Denis Drygin | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.23 per share. | 04 Feb 2022 | 23,314 | 23,314 (0%) | 0% | 0.2 | 5,362 | Common Stock |
| Regulus Therapeutics Inc | Denis Drygin | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Denis Drygin | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Denis Drygin | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) |